A phase 11 study of recombinant interferon-beta (r-hlFNg Ia) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma
1997

Study of Interferon-Beta and 5-Fluorouracil for Colorectal Cancer

Sample size: 27 publication Evidence: low

Author Information

Author(s): JK Joffel, TJ Perren, C Bradley, J Primrose, S Hallam, U Ward, JM lllingworth, PJ Selby

Primary Institution: CRF Cancer Medicine Research Unit, St James's University Hospital

Hypothesis

Does the combination of recombinant interferon-beta and 5-fluorouracil improve treatment outcomes for patients with advanced colorectal carcinoma?

Conclusion

The combination of recombinant human interferon-beta-1 a and 5-fluorouracil is tolerable but does not show a superior response rate compared to previous treatments.

Supporting Evidence

  • Four objective responses were seen among 21 evaluable patients.
  • The median survival for all patients was 8.4 months.
  • Patients who responded to therapy exhibited longer survival.
  • The regimen was generally well tolerated with mild toxicities.

Takeaway

Doctors tested a new treatment for colon cancer using two medicines together, but it didn't work better than the old treatment.

Methodology

Patients with advanced colorectal carcinoma were treated with a combination of 5-fluorouracil and recombinant interferon-beta in a non-randomized open phase II study.

Potential Biases

The study was non-randomized, which may introduce selection bias.

Limitations

The study lacked a control group for comparison and had a small sample size.

Participant Demographics

18 males and 9 females, median age 60 years.

Statistical Information

Confidence Interval

95% CI 2-36%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication